Arovella Therapeutics Limited (ASX:ALA)

Australia flag Australia · Delayed Price · Currency is AUD
0.0770
-0.0010 (-1.28%)
At close: Mar 6, 2026
-26.67%
Market Cap 92.95M
Revenue (ttm) 3.21M
Net Income (ttm) -7.93M
Shares Out 1.21B
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 373,156
Average Volume 870,126
Open 0.0780
Previous Close 0.0780
Day's Range 0.0770 - 0.0780
52-Week Range 0.0680 - 0.1250
Beta -0.20
RSI 35.63
Earnings Date Feb 25, 2026

About Arovella Therapeutics

Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly know... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 27
Stock Exchange Australian Securities Exchange
Ticker Symbol ALA
Full Company Profile

Financial Performance

In fiscal year 2025, Arovella Therapeutics's revenue was 3.44 million, an increase of 76.22% compared to the previous year's 1.95 million. Losses were -7.51 million, -14.14% less than in 2024.

Financial Statements

News

There is no news available yet.